BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3617000)

  • 1. [Information centers on undesirable effects of drugs: also on alerting function].
    Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H
    Therapie; 1987; 42(2):231-7. PubMed ID: 3617000
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
    Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
    [No Abstract]   [Full Text] [Related]  

  • 3. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1986; 41(5):327-9. PubMed ID: 3810519
    [No Abstract]   [Full Text] [Related]  

  • 4. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug nephrotoxicity. A microcomputerized databank of renal involvement and responsible "nephrotox" drugs].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1988 May; 43(3):211-7. PubMed ID: 3420569
    [No Abstract]   [Full Text] [Related]  

  • 6. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 7. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

  • 10. Rhode Island physicians' recognition and reporting of adverse drug reactions.
    Scott HD; Rosenbaum SE; Waters WJ; Colt AM; Andrews LG; Juergens JP; Faich GA
    R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
    Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
    Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
    [No Abstract]   [Full Text] [Related]  

  • 12. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products].
    Juillet Y; de Cremiers F
    Therapie; 1988; 43(5):385-8. PubMed ID: 3227498
    [No Abstract]   [Full Text] [Related]  

  • 13. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 14. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 15. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
    Bégaud B; Evreux JC; Jouglard J; Lagier G
    Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
    [No Abstract]   [Full Text] [Related]  

  • 16. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 19. Advantages of adverse-effect reporting by patients.
    Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
    [No Abstract]   [Full Text] [Related]  

  • 20. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.